CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

Phase 1

Completed

Conditions: Safety and Pharmacokinetics in Healthy Volunteer Subjects

Interventions: Drug: CC-223

First Posted Date: 2012-06-05

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT01611467

Locations: 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: Azacitidine

First Posted Date: 2012-05-16

Last Posted Date: 2019-03-19

Lead Sponsor: Celgene

Target Recruit Count: 72

Registration Number: NCT01599325

Locations: 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
The 301 Hospital- Chinese PLA General Hospital, Beijing, China
🇨🇳
The Third Hospital of Peking University, Beijing, China

and more 8 locations

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-05-08

Last Posted Date: 2017-09-20

Lead Sponsor: Celgene

Target Recruit Count: 194

Registration Number: NCT01593410

Locations: 🇨🇳
307 Hospital of Chinese PLA, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China

and more 9 locations

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215
Drug: lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-04-24

Last Posted Date: 2022-02-23

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT01583283

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

Phase 1

Completed

Conditions: Multiple Myeloma
Renal Impairment

Interventions: Drug: 2 mg Oral POM + 40 mg Oral DEX
Drug: 4 mg Oral POM + 40 mg Oral DEX

First Posted Date: 2012-04-12

Last Posted Date: 2022-11-04

Lead Sponsor: Celgene

Target Recruit Count: 25

Registration Number: NCT01575925

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇨🇦
L'Hotel Dieu de Quebec, Quebec, Canada

and more 6 locations

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Phase 2

Terminated

Conditions: Beta Thalassemia Major
Beta Thalassemia Intermedia

Interventions: Drug: SOTATERCEPT (ACE-011)

First Posted Date: 2012-04-05

Last Posted Date: 2023-06-18

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT01571635

Locations: 🇫🇷
Hopital Henri Mondor, Créteil, France
🇬🇷
Laiko General Hospital, Ampelokipi - Athens, Greece
🇬🇷
Local Institution - 300, Ampelokipi - Athens, Greece

and more 15 locations

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Oral azacitidine

First Posted Date: 2012-04-05

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 5

Registration Number: NCT01571648

Locations: 🇯🇵
Celgene Trial Site, Tokyo, Japan

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: pomalidomide

First Posted Date: 2012-04-02

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 12

Registration Number: NCT01568294

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital, Tyuuou, Tokyo, Japan
🇯🇵
Niigata Cancer Center Hospital, Niigata, Japan

and more 5 locations

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Phase 3

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Oral Azacitidine
Drug: Placebo
Other: Best Supportiv Care (BSC)

First Posted Date: 2012-03-29

Last Posted Date: 2024-01-26

Lead Sponsor: Celgene

Target Recruit Count: 216

Registration Number: NCT01566695

Locations: 🇨🇦
Local Institution - 179, Toronto, Ontario, Canada
🇺🇸
Jackson Oncology Associates PLLC, Jackson, Mississippi, United States
🇺🇸
Penn Medicine: University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

and more 193 locations

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Phase 2

Terminated

Conditions: Scleroderma, Systemic
Interstitial Lung Disease
Sclerosis, Systemic
Systemic Sclerosis
Systemic Scleroderma

Interventions: Drug: Placebo
Drug: Pomalidomide (CC-4047)

First Posted Date: 2012-03-21

Last Posted Date: 2023-12-01

Lead Sponsor: Celgene

Target Recruit Count: 23

Registration Number: NCT01559129

Locations: 🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia
🇵🇱
SPSK Nr 7 Slaskiego Uniwersytetu Medycznego, Oddzial Chorob Wewnetrznych i Reumatologii, Katowice, Poland
🇵🇱
Instytut Reumatologii, Klinika i Poliklinika Ukladowych Chorób Tkanki Lacznej, Warszawa, Poland

and more 53 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy